Finance

Retail bets on zero day options are growing, but they may come at a price

Products You May Like

It’s a sophisticated trading strategy that’s becoming more accessible to retail investors.

The strategy: Zero days-to-expiration options — which is essentially a one-day bet on the direction of the markets.

And CBOE Global Markets CEO Ed Tilly is in the thick of it. His company offers them all five weekdays.

“It’s really become attractive and garnered a lot of interest in being able to express that opinion [on the market] in the short term,” Tilley told CNBC’s “ETF Edge” earlier this week.

Zero days-to-expiration options are contracts that expire the same day they’re traded. Tilly believes these options are appealing to investors by allowing them to invest at the shortest duration of time left in a contract.

“At the end of the trading day, the next result of that trade is settled in cash — not physically delivered like a stock or an ETF,” he said.

Most effective as a tool for pros?

Simplify Asset Management also offers these zero day-to-expiration options. Michael Green, the firm’s chief strategist and portfolio manager, also notes they’ve become especially attractive to individuals.

“About a third of [our] trades are coming from retail, and about two-thirds are coming from institutional,” he said.

Despite growing retail interest, Green emphasizes zero days-to-expiration options may be most effective as a tool for pros.

“We use the phrase sophisticated retail investors, and I think there’s actually a really important distinction there,” Green said. “In general, those who are buying options on a consistent basis are doing more speculation than they actually are being sophisticated in terms of a return profile. It tends to be a losing bet.”

Disclaimer

Products You May Like

Articles You May Like

Disney stock surges on streaming growth, guidance
Homebuilder deal activity is surging, fueled by major Japanese buyers
China’s Alibaba releases AI search tool for small businesses in Europe and the Americas
Caligan picks up a stake in Verona Pharma, seeing an opportunity to generate more value
Capri and Tapestry abandon plans to merge, citing regulatory hurdles